List of Excipients in Branded Drug PHENTERMINE RESIN

« Back to Dashboard

Generic Drugs Containing PHENTERMINE RESIN

Company	Ingredient	NDC	Excipient
Lannett Company Inc	phentermine resin	0527-1398	ALCOHOL
Lannett Company Inc	phentermine resin	0527-1398	ALUMINUM OXIDE
Lannett Company Inc	phentermine resin	0527-1398	BUTYL ALCOHOL
Lannett Company Inc	phentermine resin	0527-1398	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Lannett Company Inc	phentermine resin	0527-1398	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in PHENTERMINE RESIN?

# Of NDCs	Excipient
1	ALCOHOL
1	ALUMINUM OXIDE
1	BUTYL ALCOHOL
1	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
1	D&C YELLOW NO. 10

Phentermine Resin Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: October 5, 2026

Phentermine resin is best evaluated as a drug-resin complex for modified release, taste masking, abuse-deterrence positioning, or improved dosage-form handling. The commercial opportunity is strongest in once-daily oral products, pediatric or geriatric multiparticulates, orally disintegrating systems, and combination products that differentiate release profiles. The principal development risks are resin capacity, dose-loading limits, incomplete drug release, alcohol effects, controlled-substance compliance, and the absence of a clear regulatory precedent for an approved phentermine-resin product.

What is phentermine resin and how does it differ from phentermine hydrochloride?

Phentermine resin generally refers to phentermine bound to an ion-exchange resin, rather than phentermine hydrochloride blended directly with conventional tablet excipients. The resin-drug complex is typically an insoluble or sparingly soluble polymeric material that releases phentermine when exposed to ions in gastrointestinal fluid.

Attribute	Phentermine hydrochloride	Phentermine-resin complex
Drug form	Soluble salt	Drug bound to polymeric resin
Release profile	Usually immediate release	Potentially modified or delayed release
Primary formulation purpose	Rapid systemic exposure	Controlled release, taste masking, or physical handling
Dose calculation	Based on salt strength	Based on active drug loading and resin complex assay
Regulatory precedent	Established approved products	Product-specific development and characterization required
Manufacturing risk	Relatively low	Higher due to loading, washing, drying, and release control
Patent opportunity	Limited for the old active ingredient	Formulation, process, release profile, and combination claims

Phentermine is a sympathomimetic amine used for short-term weight-management therapy in the United States. Approved products include immediate-release phentermine hydrochloride tablets and capsules, as well as low-dose tablets such as Lomaira. Phentermine is also used in the extended-release phentermine/topiramate product Qsymia. FDA labeling identifies phentermine as a Schedule IV controlled substance, which affects manufacturing, inventory, distribution, recordkeeping, and diversion controls (FDA, 2023a; FDA, 2023b).

What excipient strategy is appropriate for a phentermine-resin product?

The formulation should treat the resin as a functional drug-delivery component rather than as a passive excipient. A practical strategy uses the resin complex for the primary performance attribute and limits conventional excipients to flow, compression, coating, stability, and palatability functions.

Which resins are most relevant?

Candidate resins include strong-acid cation-exchange materials, weak-acid cation-exchange materials, and pharmaceutical-grade methacrylic or polystyrene-divinylbenzene systems. The selection depends on phentermine’s ionization behavior, target release duration, dosage form, and acceptable residual-ion profile.

Important resin attributes include:

• Exchange capacity, usually expressed in milliequivalents per gram.
• Particle-size distribution.
• Cross-link density.
• Moisture content.
• Residual monomers and extractables.
• Heavy metals and elemental impurities.
• Microbial quality.
• Drug-loading uniformity.
• Release performance across pH conditions.
• Compatibility with coating solvents and compression forces.

Phentermine is a basic amine. Cation-exchange resins can bind the protonated drug through ionic interactions. The complex must release the active ingredient in gastrointestinal media through ion exchange. Sodium, potassium, hydrogen, and other endogenous ions can compete with the drug for binding sites.

Which supporting excipients are commercially practical?

Formulation function	Candidate excipient classes	Development purpose
Matrix protection	Microcrystalline cellulose, mannitol, dibasic calcium phosphate	Improves compressibility and tablet robustness
Flow control	Colloidal silicon dioxide, talc	Reduces segregation and improves powder handling
Binder	Povidone, copovidone, hydroxypropyl cellulose	Supports granulation and mechanical strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes release from immediate-release dosage forms
Barrier coating	Ethylcellulose, hypromellose, polyvinyl alcohol	Controls water penetration and drug release
Taste masking	Film coat, lipid coat, polymer overcoat	Reduces bitterness and oral exposure before swallowing
Osmotic or pH control	Citrate, phosphate, carbonate buffers	Adjusts local ion exchange and release behavior
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports compression and ejection
Capsule system	Gelatin or hypromellose shells	Enables multiparticulate delivery

Excipients should be selected against the FDA Inactive Ingredient Database and applicable compendial standards. The database provides precedent for route, dosage form, and maximum potency, but it does not establish automatic acceptance for a new phentermine-resin product (FDA, 2024a).

What formulation architectures provide the strongest commercial differentiation?

Extended-release multiparticulates

Drug-resin particles can be coated with ethylcellulose, hypromellose, polyvinyl acetate dispersions, or acrylic polymers. The coating controls fluid access and ion exchange. Multiparticulates can be filled into capsules or compressed into tablets.

This architecture offers several advantages:

• More flexible release control than a single monolithic tablet.
• Lower sensitivity to tablet fracture.
• Potential for sprinkle administration.
• Better dose uniformity across different particle populations.
• Ability to combine immediate-release and extended-release fractions.

A commercial product could use an uncoated fraction for early exposure and coated particles for later release. That approach could produce a biphasic profile without relying on a conventional matrix tablet.

Orally disintegrating tablets

A resin complex can reduce the perception of bitterness if the drug remains bound during short oral residence. The formulation would require rapid disintegration, low friability, and limited drug release in saliva. Mannitol, crospovidone, flavor systems, and a polymeric taste-masking coat are common development tools.

The main technical risk is premature phentermine release in the mouth. A taste-masking claim requires sensory testing and dissolution testing in simulated saliva, not only standard compendial dissolution.

Liquid suspensions

A resin complex can convert a soluble, bitter drug into a suspendable particulate system. This may support pediatric, geriatric, or swallowing-impaired populations. The formulation would require control of sedimentation, redispersibility, particle-size growth, microbial preservation, and dose uniformity.

Commercial potential is constrained by phentermine’s labeling and controlled-substance status. A liquid product may create diversion and measurement risks that do not exist to the same extent with unit-dose tablets or capsules.

Abuse-deterrent or tamper-resistant products

A resin complex may reduce extractability in certain solvents or make dose dumping more difficult. Those properties do not automatically establish an abuse-deterrent product. FDA abuse-deterrence claims require comparative testing and appropriate labeling under the agency’s abuse-deterrent guidance (FDA, 2015).

A formulation company should avoid positioning phentermine resin as abuse deterrent unless the product demonstrates relevant resistance to manipulation, extraction, crushing, and rapid release. A more defensible initial claim may be "modified-release" or "taste-masked," depending on data.

How should phentermine-resin release be characterized?

A robust analytical package should include resin loading, free drug, total drug, release kinetics, and stability. Standard dissolution alone is insufficient because the drug remains associated with the resin during early stages of testing.

Recommended studies include:

1. Drug-loading assay by a validated chromatographic method.
2. Free-versus-bound phentermine measurement.
3. Ion-exchange capacity and equilibrium binding studies.
4. Dissolution across acidic, neutral, and mildly basic media.
5. Agitation-speed sensitivity.
6. Food-effect screening.
7. Alcohol-dose-dumping assessment.
8. Particle-size and coating-thickness correlation.
9. Stability under heat and humidity.
10. Extractables and leachables testing.
11. In vitro alcohol and solvent extraction studies.
12. In vivo pharmacokinetic comparison with an approved phentermine product.

The target release profile should be linked to clinical pharmacology. A formulation that lowers the maximum concentration but materially increases exposure or half-life may require a new safety assessment. Phentermine labeling warns about cardiovascular and central nervous system effects, contraindications, tolerance, dependence, and interactions with monoamine oxidase inhibitors (FDA, 2023a).

What FDA regulatory pathway applies to phentermine resin?

A phentermine-resin product could potentially use an abbreviated new drug application if it is therapeutically equivalent to a reference product and meets the applicable requirements for dosage form, strength, route, release characteristics, and labeling. A materially different modified-release product would more likely require a 505(b)(2) application or a full NDA, depending on the formulation and clinical evidence.

Product concept	Likely U.S. pathway	Primary regulatory issue
Immediate-release generic tablet using conventional excipients	ANDA	Bioequivalence and pharmaceutical equivalence
Same strength with resin complex but equivalent release	ANDA only if FDA accepts equivalence	Complex formulation and release comparability
New extended-release phentermine product	505(b)(2) or NDA	Clinical pharmacology, safety, and dose justification
Pediatric liquid or sprinkle formulation	505(b)(2) or NDA	Dosing, stability, palatability, and controlled-substance controls
Phentermine/topiramate resin combination	505(b)(2) or NDA	Combination-product safety and distinct pharmacokinetics
Abuse-deterrent formulation	505(b)(2) or NDA	Comparative manipulation and extraction studies

FDA approval of a phentermine-resin product would not follow solely from approval of phentermine hydrochloride. The resin can change absorption, exposure, dose proportionality, food effects, and drug-drug interaction behavior.

What is the Orange Book status of phentermine resin?

The FDA Orange Book lists approved drug products and associated patents or exclusivity where applicable. Conventional phentermine hydrochloride products have longstanding approval histories, while the specific product concept "phentermine resin" should not be assumed to have an Orange Book listing merely because phentermine hydrochloride products are listed.

Regulatory issue	Commercial implication
Approved phentermine hydrochloride products	Established reference-product and generic framework
Phentermine-resin complex	Product-specific approval required
Orange Book patent listing	Depends on an approved product and qualifying patent
Method-of-use protection	Potentially narrower than formulation protection
Controlled-substance status	Applies to manufacturing and distribution regardless of resin technology
Exclusivity	Depends on the approved application, not merely the active ingredient

The core active-ingredient opportunity is limited because phentermine has been marketed for decades. Commercial protection must therefore come from a differentiated release profile, dosage form, combination, manufacturing process, or clinically meaningful use.

What patents could protect a phentermine-resin product?

The strongest patent strategy would center on composition and performance, not broad claims to phentermine itself.

Composition claims

Potential claims could cover:

• A defined phentermine-to-resin weight ratio.
• A specified exchange capacity.
• A selected resin chemistry.
• A particle-size distribution.
• A coated drug-resin complex.
• A composition containing immediate-release and extended-release resin fractions.
• A defined free-drug percentage.

Composition claims are commercially valuable because they can read directly on the marketed product. Their weakness is that competitors may design around the resin type, loading range, coating polymer, or particle-size limits.

Release-profile claims

Claims may define:

• Percentage released at specified dissolution intervals.
• Reduced peak plasma concentration.
• Extended exposure over a specified period.
• Resistance to alcohol-induced dose dumping.
• A biphasic release profile.

These claims can be difficult to enforce if the claim depends on biological or dissolution results that vary by test method. The patent should specify robust analytical conditions and meaningful numerical ranges.

Manufacturing claims

Manufacturing patents may cover:

• Drug loading in a selected solvent or pH range.
• Washing and drying conditions.
• Coating the resin complex.
• Controlling residual solvent or free phentermine.
• Continuous or high-shear processing.
• Methods that improve loading uniformity.

Process claims are useful when the manufacturing route is difficult to reproduce, but they may be harder to enforce against an independently manufactured product.

Method-of-use claims

Potential use claims could target:

• Once-daily weight-management treatment.
• Reduced peak-related adverse effects.
• Specific patient populations.
• Combination treatment with another anti-obesity agent.
• Improved adherence through a modified-release profile.

Method-of-use protection is usually narrower than product protection and may face infringement-proof challenges in generic markets.

When does phentermine lose exclusivity?

The basic phentermine active-ingredient exclusivity period has long expired. The principal commercial question is not when phentermine itself loses exclusivity, but whether a new resin formulation can obtain enforceable patent protection and regulatory exclusivity.

For a new application, possible protection may include:

• Five-year new chemical entity exclusivity, generally unavailable where the active ingredient is already approved.
• Three-year exclusivity for certain new clinical investigations supporting a change in labeling or dosage form.
• Orphan-drug exclusivity only if the product qualifies for an orphan indication.
• Patent-term adjustment or patent-term extension where statutory requirements are met.
• Formulation and manufacturing patents, typically providing the most relevant protection for a resin product.

The commercial launch date depends on the approved product’s Orange Book listings, patent litigation, Paragraph IV certifications, settlement terms, and any applicable regulatory exclusivity.

Which companies are challenging phentermine products?

Generic manufacturers have long marketed conventional phentermine products. The competitive threat to a new phentermine-resin product would come from several groups:

1. Generic manufacturers selling low-cost immediate-release phentermine.
2. Developers of extended-release or combination obesity products.
3. Specialty pharmaceutical companies pursuing 505(b)(2) reformulations.
4. Resin and modified-release technology licensors.
5. Compounding pharmacies, where legally permissible and subject to applicable restrictions.

A resin product must therefore offer a clear advantage over inexpensive immediate-release phentermine. A modest formulation improvement without a measurable adherence, tolerability, or dosing benefit may not support premium pricing.

What licensing opportunities exist for phentermine resin technology?

Licensing value is likely to reside in the delivery platform rather than in phentermine. Potential transaction structures include:

Deal structure	Suitable asset	Commercial rationale
Technology license	Drug-resin binding and coating platform	Allows use across multiple oral drugs
Product-specific license	Patented phentermine-resin formulation	Focused development and commercialization
Co-development agreement	New extended-release or combination product	Shares clinical and regulatory costs
Manufacturing supply agreement	Qualified resin complex or coated particles	Provides process control
Out-license to a generic company	Complex generic formulation	Uses established ANDA capabilities
Regional license	U.S., Europe, or emerging markets	Reflects controlled-substance and obesity-market differences

A platform license may be more valuable than a single-product license if the resin technology can be applied to other bitter, basic, controlled, or high-potency drugs. The license should define ownership of formulation improvements, analytical methods, process changes, and regulatory data.

What geographic markets offer the best opportunity?

The United States has the clearest commercial reference market but also the strictest controlled-substance and generic-substitution requirements. European opportunities depend on country-specific authorization, controlled-drug rules, and obesity-treatment standards. Markets with high demand for oral weight-management products may support a modified-release product, but pricing and reimbursement can differ sharply.

Region	Opportunity	Principal barrier
United States	Generic or 505(b)(2) reformulation	Controlled-substance compliance and low-cost generics
European Union	Modified-release oral product	Decentralized pricing and national reimbursement
Latin America	Branded oral appetite suppressant	Regulatory variability and counterfeit risk
Middle East	Specialty obesity product	Controlled-drug import requirements
Asia-Pacific	Local licensing or manufacturing	Country-specific approval and distribution controls

A global patent filing should prioritize jurisdictions where phentermine is marketed, obesity treatment is commercially significant, and local formulation manufacturing is feasible. Patent value is limited in countries where regulatory enforcement is weak or where phentermine use is restricted.

What generic launch risks exist for a phentermine-resin product?

The primary launch risk is substitution by conventional phentermine. A generic immediate-release product may be clinically acceptable for the same broad treatment purpose and priced substantially below a novel resin product.

Other risks include:

• Failure to demonstrate bioequivalence to the selected reference product.
• An overly complex release profile that requires clinical trials.
• Dose dumping in the presence of alcohol.
• Inconsistent resin loading between batches.
• Unacceptable residual monomers or extractables.
• Controlled-substance manufacturing delays.
• Limited payer willingness to reimburse a reformulation.
• Patent claims that are easy to design around.
• Insufficient evidence of improved adherence or tolerability.
• Commercial competition from GLP-1 receptor agonists and other modern obesity therapies.

The strongest launch position would pair a defensible patent estate with a specific clinical benefit, such as once-daily dosing, lower peak exposure, improved tolerability, or a dosage form that materially improves administration.

How strong is the patent estate for phentermine resin?

The patent estate would be moderate if it covers only a resin-drug complex broadly. It would be stronger if the developer controls a narrow but difficult-to-design-around combination of:

• Specific resin chemistry.
• Defined drug loading.
• Coating architecture.
• Release profile.
• Manufacturing process.
• Clinical or pharmacokinetic advantage.
• Approved labeling supported by patent claims.

The estate would be weak if it relies on generic claims to "phentermine bound to an ion-exchange resin" without validated performance limits. Competitors could potentially change the resin, coating polymer, particle size, or drug-loading range.

Key Takeaways

• Phentermine resin is primarily a modified-release and taste-masking technology, not a conventional inactive excipient.
• The most promising dosage forms are coated multiparticulates, extended-release capsules, orally disintegrating tablets, and selected liquid suspensions.
• The core phentermine active ingredient has no meaningful new-molecule exclusivity opportunity.
• Commercial protection must come from formulation, release profile, manufacturing, combination, or method-of-use patents.
• An ANDA may be possible only if the resin product can meet the relevant equivalence requirements. A materially different product is more likely to require a 505(b)(2) application or NDA.
• Immediate-release generic phentermine is the principal pricing threat.
• The best licensing assets are transferable resin-binding, coating, and controlled-release technologies.
• Controlled-substance controls, dose dumping, resin loading, and bioequivalence are the principal development barriers.
• A premium product requires a measurable clinical or adherence advantage over inexpensive immediate-release phentermine.

FAQs

Can phentermine resin be used in an extended-release capsule?

Yes. A coated phentermine-resin complex can be filled into capsules as multiparticulates. The formulation must demonstrate uniform drug loading, controlled release, stability, and acceptable pharmacokinetics.

Is phentermine resin an excipient listed in the FDA Inactive Ingredient Database?

No general assumption should be made that a phentermine-resin complex qualifies as a conventional inactive ingredient. The resin-drug complex is part of the active pharmaceutical product and requires product-specific regulatory evaluation.

Can phentermine resin support an abuse-deterrent claim?

Potentially, but resin binding alone is insufficient. FDA-recognized abuse-deterrence claims require comparative manipulation, extraction, and dose-dumping data.

Would a phentermine-resin product be therapeutically equivalent to Adipex-P?

Not automatically. A modified-release or resin-bound product may have different absorption and exposure characteristics from immediate-release phentermine hydrochloride. Equivalence would depend on the approved reference product, formulation, labeling, and FDA requirements.

Is a phentermine-resin formulation attractive for licensing?

Yes, if it has issued patents, reproducible manufacturing, a demonstrated pharmacokinetic advantage, and a regulatory pathway that supports differentiated pricing. A platform applicable to multiple basic or bitter drugs would improve licensing value.

References

1. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. https://www.fda.gov
2. U.S. Food and Drug Administration. (2023a). Adipex-P (phentermine hydrochloride) prescribing information. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2023b). Lomaira (phentermine hydrochloride) prescribing information. https://www.accessdata.fda.gov
4. U.S. Food and Drug Administration. (2024a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
5. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: U.S. Pharmacopeial Convention.